ASRS ’24: C1q Inhibition and Metformin for AMD

New Retina Radio by Eyetube
05/09/2024 23 min
ASRS ’24: C1q Inhibition and Metformin for AMD

Listen "ASRS ’24: C1q Inhibition and Metformin for AMD"

Descargar episodio

Episode Synopsis

Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest research regarding potential interactions between metformin and AMD development in non-diabetic patients. Does the future of care include metformin as prophylaxis? Stick with us to find out. 

More episodes of the podcast New Retina Radio by Eyetube

New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care 10/10/2025
The Nuts and Bolts of GA Therapy: The Opening Sessions 09/10/2025
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision 02/10/2025
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation 02/10/2025
Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations 02/10/2025
Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention 02/10/2025
New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab 26/09/2025
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR 04/09/2025
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders 21/08/2025
New Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic Retinopathy 13/08/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA